Galvin Gaustad & Stein’s Vertex Pharmaceuticals VRTX Stock Holding History

Galvin Gaustad & Stein’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.7M	Buy	35,233 +924	+3%	+$431K	1.26%	27
2025 Q4	$15.6M	Buy	34,309 +1,167	+4%	+$503K	1.21%	32
2025 Q3	$13M	Buy	33,142 +10,252	+45%	+$4.28M	1.05%	43
2025 Q2	$10.2M	Buy	22,890 +1,529	+7%	+$705K	0.88%	49
2025 Q1	$10.4M	Sell	21,361 -367	-2%	-$171K	0.93%	48
2024 Q4	$8.75M	Sell	21,728 -233	-1%	-$108K	0.78%	52
2024 Q3	$10.2M	Sell	21,961 -14,724	-40%	-$7.07M	0.91%	45
2024 Q2	$17.2M	Buy	36,685 +9,280	+34%	+$4.03M	1.6%	27
2024 Q1	$11.5M	Buy	27,405 +6,358	+30%	+$2.69M	1.05%	41
2023 Q4	$8.56M	Buy	+21,047	New	+$7.78M	0.8%	46

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Galvin Gaustad & Stein's VRTX Position: Q1 2026 in Review

Galvin Gaustad & Stein increased its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q1 2026, buying an estimated $431K and bringing the position to 35,233 shares worth $15.7M. The position accounts for 1.26% of the portfolio, ranked #27.

Galvin Gaustad & Stein first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $17.2M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Galvin Gaustad & Stein held 35,233 shares of Vertex Pharmaceuticals worth $15.7M as of Q1 2026.
Galvin Gaustad & Stein bought 924 Vertex Pharmaceuticals shares in Q1 2026, an estimated $431K.
Vertex Pharmaceuticals made up 1.26% of Galvin Gaustad & Stein's portfolio in Q1 2026, its #27 holding.
Galvin Gaustad & Stein first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Galvin Gaustad & Stein's Vertex Pharmaceuticals position peaked at $17.2M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Galvin Gaustad & Stein's 13F filing for Q1 2026, filed 14 May 2026.